FDA approves ImpediMed's device

The FDA has granted ImpediMed approval to market its L-Dex U400 device for use in assessing lymphoedema, a condition that affects women who underwent surgery for breast cancer. The clearance will grant the Australian firm access to the $4.4 billion international market for lymphoedema therapies.

View Full Article in:

Herald Sun (Melbourne, Australia) (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Fort Worth, TX